Cargando…

A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer

BACKGROUND: This Phase 2b study compared the efficacy and toxicity of belotecan and topotecan in recurrent ovarian cancer. METHODS: Patients with platinum-sensitive recurrent or platinum-resistant recurrent ovarian cancer (PRROC) were randomised 1:1 to receive belotecan 0.5 mg/m(2) or topotecan 1.5 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hee Seung, Park, Sang-Yoon, Park, Chan-Yong, Kim, Young Tae, Kim, Beob-Jong, Song, Yong Jung, Kim, Byoung-Gie, Kim, Yong Beom, Cho, Chi-Heum, Kim, Jong-Hyeok, Song, Yong Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853132/
https://www.ncbi.nlm.nih.gov/pubmed/32994466
http://dx.doi.org/10.1038/s41416-020-01098-8